These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28017893)

  • 1. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
    Todeschini P; Salviato E; Paracchini L; Ferracin M; Petrillo M; Zanotti L; Tognon G; Gambino A; Calura E; Caratti G; Martini P; Beltrame L; Maragoni L; Gallo D; Odicino FE; Sartori E; Scambia G; Negrini M; Ravaggi A; D'Incalci M; Marchini S; Bignotti E; Romualdi C
    Cancer Lett; 2017 Mar; 388():320-327. PubMed ID: 28017893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types.
    Kobayashi M; Sawada K; Nakamura K; Yoshimura A; Miyamoto M; Shimizu A; Ishida K; Nakatsuka E; Kodama M; Hashimoto K; Mabuchi S; Kimura T
    J Ovarian Res; 2018 Sep; 11(1):81. PubMed ID: 30219071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
    Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
    Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer.
    Niemira M; Erol A; Bielska A; Zeller A; Skwarska A; Chwialkowska K; Kuzmicki M; Szamatowicz J; Reszec J; Knapp P; Moniuszko M; Kretowski A
    Sci Rep; 2023 Nov; 13(1):19287. PubMed ID: 37935712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
    Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
    Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
    Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
    Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.
    Zhou J; Gong G; Tan H; Dai F; Zhu X; Chen Y; Wang J; Liu Y; Chen P; Wu X; Wen J
    Oncol Rep; 2015 Jun; 33(6):2915-23. PubMed ID: 25962395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer.
    Kan CW; Hahn MA; Gard GB; Maidens J; Huh JY; Marsh DJ; Howell VM
    BMC Cancer; 2012 Dec; 12():627. PubMed ID: 23272653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
    Shah JS; Gard GB; Yang J; Maidens J; Valmadre S; Soon PS; Marsh DJ
    Gynecol Oncol; 2018 Jan; 148(1):181-188. PubMed ID: 29132874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of Critical Genes Involved in Metastasis and Prognosis of High-Grade Serous Ovarian Cancer by Gene Expression Profile Data.
    Wang R; Du X; Zhi Y
    J Comput Biol; 2020 Jul; 27(7):1104-1114. PubMed ID: 31725318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OCaMIR-A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study.
    Kandimalla R; Wang W; Yu F; Zhou N; Gao F; Spillman M; Moukova L; Slaby O; Salhia B; Zhou S; Wang X; Goel A
    Clin Cancer Res; 2021 Aug; 27(15):4277-4286. PubMed ID: 34035068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes virus microRNA expression and significance in serous ovarian cancer.
    Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
    PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.